Participating in a Memorial Day commemoration, Joe Biden made his first public address since the announcement of his Stage 4 prostate cancer diagnosis at a Biden family event in his home state of ...

(NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

As researchers in the laboratories and clinics of Fred Hutch Cancer Center strive to develop tomorrow’s cures for cancer, many are also pursuing innovative ways to improve the experience of people ...

TOKYO- Olympus is expanding its cancer care portfolio with the acquisition of a medtech company based in Israel. Olympus is ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the ...

Olympus has signed a definitive agreement to acquire BioProtect for $270 million, adding biodegradable balloon spacer ...

The latest PSA grading updates are reshaping card values, submission costs, and long-term collector ROI. If you are a PSA fan, this blog is definitely for you. The latest PSA grading updates are ...

As of May 21, 2026, results from all seven members of the Magnificent Seven, including Nvidia, Alphabet, Apple, Microsoft, ...

Extended pelvic lymph node dissection (ePLND) after radical prostatectomy failed to improve survival in intermediate- and ...

Vir Biotechnology has a cash runway into 2028 and pivotal 2026 catalysts for its lead hepatitis drugs. Learn why VIR stock is a buy.

Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- ...

Pro forma gross profit for the quarter was $15 million, yielding a pro forma gross margin of 62.9% compared to 68.0% for fiscal Q1 ended March 31, 2025, with the difference primarily related to tissue ...